Pfizer announced on Wednesday that its coronavirus vaccine developed with partner BioNTech is more than 95 percent effective during the final analysis of its Phase 3 trial.
A total of 20 million Americans could be vaccinated with Pfizer's COVID-19 vaccine before the end of the year, according to a top official involved in the government's vaccine initiative.
Pharmaceutical giant Pfizer reported no major safety problems on their COVID-19 vaccine trial after more than 12,000 people received their second of two doses.
COVID-19 has resulted in a lot of economic and health constraints in the country. Pfizer aims to get a vaccine ready by fall to help get the country back on its feet.
In the past weeks, pharmaceutical and biotech companies have aimed to develop COVID-19 vaccines, which are now scheduled for human trials. Read on to find out how far each company has gone.